tetano
Editor, Senior Moderator
Am J Cardiovasc Drugs
. 2021 Nov 24.
doi: 10.1007/s40256-021-00511-8. Online ahead of print.
Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis
Adrija Hajra[SUP] 1 [/SUP], Manasvi Gupta[SUP] 2 [/SUP], Binita Ghosh[SUP] 3 [/SUP], Kumar Ashish[SUP] 4 [/SUP], Neelkumar Patel[SUP] 5 [/SUP], Gaurav Manek[SUP] 2 [/SUP], Devesh Rai[SUP] 6 [/SUP], Dhrubajyoti Bandyopadhyay[SUP] 7 [/SUP], Carl J Lavie[SUP] 8 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus causing coronavirus disease 2019 (COVID-19), has affected human lives across the globe. On 11 December 2020, the US FDA granted an emergency use authorization for the first COVID-19 vaccine, and vaccines are now widely available. Undoubtedly, the emergence of these vaccines has led to substantial relief, helping alleviate the fear and anxiety around the COVID-19 illness for both the general public and clinicians. However, recent cases of vaccine complications, including myopericarditis, have been reported after administration of COVID-19 vaccines. This article discusses the cases, possible pathogenesis of myopericarditis, and treatment of the condition. Most cases were mild and should not yet change vaccine policies, although prospective studies are needed to better assess the risk-benefit ratios in different groups.
. 2021 Nov 24.
doi: 10.1007/s40256-021-00511-8. Online ahead of print.
Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis
Adrija Hajra[SUP] 1 [/SUP], Manasvi Gupta[SUP] 2 [/SUP], Binita Ghosh[SUP] 3 [/SUP], Kumar Ashish[SUP] 4 [/SUP], Neelkumar Patel[SUP] 5 [/SUP], Gaurav Manek[SUP] 2 [/SUP], Devesh Rai[SUP] 6 [/SUP], Dhrubajyoti Bandyopadhyay[SUP] 7 [/SUP], Carl J Lavie[SUP] 8 [/SUP]
Affiliations
- PMID: 34817850
- DOI: 10.1007/s40256-021-00511-8
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus causing coronavirus disease 2019 (COVID-19), has affected human lives across the globe. On 11 December 2020, the US FDA granted an emergency use authorization for the first COVID-19 vaccine, and vaccines are now widely available. Undoubtedly, the emergence of these vaccines has led to substantial relief, helping alleviate the fear and anxiety around the COVID-19 illness for both the general public and clinicians. However, recent cases of vaccine complications, including myopericarditis, have been reported after administration of COVID-19 vaccines. This article discusses the cases, possible pathogenesis of myopericarditis, and treatment of the condition. Most cases were mild and should not yet change vaccine policies, although prospective studies are needed to better assess the risk-benefit ratios in different groups.